Rachel Beairsto reporting for the Cardiology Advisor writes that a new study shows diabetes duration increases risk of cardiorenal effects developing. However, both glucagon-like-peptide-1 analogs liraglutide and semaglutide appear to reduce risk for cardiorenal...